Physician profile

Mark E Nielson

Anesthesiology · Muncie, IN

NPI 1942407838

$11,590.26

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$233.69

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Encore Medical, Lp $10,033.25 2019-2021
Medtronic, INC. $587.59 2021-2024 Kyphon Express II Kyphopak Tray
Pacira Pharmaceuticals Incorporated $226.71 2019-2021
Spr Therapeutics, INC $214.68 2021-2023 Sprint Pns System
Boston Scientific Corporation $196.38 2021
Avanos Medical $162.50 2019
Abbott Laboratories $115.42 2021
Stryker Corporation $33.79 2019
Angiodynamics, INC. $19.94 2023 Venacure 1470 Pro

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark E Nielson

$11,590.26

in general payments reported 2019-2025

Years
2019-2024
Top company
Encore Medical, Lp

https://glasscript.com/doctor/1016644/mark-e-nielson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.